AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
AQB

AquaBounty Technologies Inc. Common Stock (AQB) fair value

Consumer Defensive · Farm Products · NASDAQ · United States
$1.11+8.82%
Market cap $5MNext earnings 2026-10-27Updated Oct 17, 2026
Add earnings to calendarGoogle
Our verdict
Trades 46% above our fair value
Price
$1.11
Model fair valueConfidence: low
about $0.76
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Net cash floor and Analyst consensus.
ACCE opinionAquaBounty Technologies Inc. Common Stock (AQB)
Fair value
Not available
ACCE price target
$0.60
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $1.11 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
26
out of 100
Analysts
0% buy
1 covering
P/E
0.0x
forward 0.0x
1-year return
-27.9%
Dividend yield
0.00%

AquaBounty Technologies Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

AquaBounty Technologies grows genetically engineered Atlantic salmon in land-based recirculating farms, selling fish under its AquAdvantage brand, with its main production site in Indiana and a smaller one in Canada. The case for a closer look is thin: revenue fell 93.5% year over year, gross margin sits at -789%, and ROE is -50.2%, so the business is currently shrinking and losing money on every fish it sells. The company's pitch rests on land-based farming insulating it from ocean disease, sea lice and climate risk, and on regulatory clearance for its salmon, but none of that is visible in the reported economics yet. At a $6M market cap with no index membership and a score of 26/100, the question for a portfolio manager is whether a restructuring or a successful scale-up is credible enough to justify the work, and on current figures that bar has not been met.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • severe
    Negative FCF and collapsing revenue
    Free cash flow is $-8.7M against a $5M market cap, and revenue is down 93.5% year over year with gross margin at -789%. Cash burn of this size relative to equity value raises going-concern questions.
  • high
    Negative equity and leverage
    Debt/Equity is -1.86, meaning liabilities exceed assets. ROE of -50.2% shows losses are eroding the capital base.
  • moderate
    Price above model fair value
    The $1.10 price sits above the ACCE fair value of $0.60 (range $0.30 to $1.03), and the score slipped from 28 to 26 over 90 days.

AI research notes

AI-assisted·How I use AIWritten Oct 16, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Over five years, revenue has grown by an average of 168.6% per year, showing the business has expanded rapidly from a small base.
  • Earnings per share came in exactly as expected, with an EPS of -0.88 against an expected -0.88 in the latest report.
  • The diluted share count rose only 0.4% last fiscal year, so existing shareholders have not been heavily diluted.
Why it could disappoint
  • Revenue fell 93.5% year over year in the latest 10-Q, a sharp contraction in the core business.
  • Free cash flow over the last twelve months was negative $9M, so the business is consuming cash rather than generating it.
  • Analysts' mean price target of $1.00 sits 9.1% below the $1.10 share price, and only 0% of covering analysts rate it Buy.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 27, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where AQB's valuation models land
Price
$1.11
Model fair valueConfidence: low
about $0.76
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish0% buy · 1 covering analyst
● Strong buy 0● Buy 0● Hold 1● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+0.0%
1 month
+6.7%
3 months
+22.0%
6 months
+13.3%
YTD
+19.4%
1 year
-27.9%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$0.60first publication$1.03

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full AQB page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value37Quality13Momentum47Total26
Valuation
Trailing P/E
0.0x
Forward P/E
0.0x
PEG
0.00
P/B
1.91x
EV / Revenue
7.7x
Book value/sh
$0.55
Enterprise value
$9M
Profitability
ROE
-50.2%
FCF yield
-157.22%
ROIC
no data
Health and risk
Debt / equity
-1.86
Dividend yield
0.00%
Beta
1.48

Price

-25.0% · 1Y

Ask anything about AQB

Answered from AquaBounty Technologies Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 2.3x
ROEbetter than 33% of peers
low -393%-50%high 28%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
AQB AquaBounty Technologies Inc. Common Stock$1.11----50.2%1326
AGRZ Agroz Inc. Ordinary Shares$2.93--1.9x26.7%7862
PVA.MC Pescanova, S.A.€0.22---1.4%3229
TULP Bloomia Holdings Inc. Common Stock$2.28----93.5%2220
ALAGR.PA AgroGeneration SA€0.04--2.3x27.9%7455
SDOT Sadot Group Inc. Common Stock$7.37----392.8%1337
ALKKO.PA KKO International SA€0.06---0.9%4742

Sector report card

Where AQB ranks against its sector peers on each metric.

Computing percentiles…
  • TMX Newsfile•Sep 15, 2026
    AquaBounty Announces Engagement of Colliers as Exclusive Agent for its Ohio Property
  • TMX Newsfile•Aug 6, 2026
    AquaBounty Technologies Announces Expansion of Strategic Alternatives Review to Include Power Infrastructure Development Opportunities
  • PR Newswire•Jun 27, 2026
    "UK-India Free Trade Agreement will be India's most comprehensive agreement so far": Piyush Goyal at UK-India Week 2026
18 filings of 36
October 2026
Oct 8
8-KCurrent reportPeriod 2026-10-07
View on SEC →
August 2026
Aug 6
8-KCurrent reportPeriod 2026-08-06
View on SEC →
Aug 6
10-QQuarterly reportPeriod 2026-06-30
View on SEC →
15 more filings + AI summaries on Investor+.INVESTOR